Literature DB >> 20213118

Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.

Xi-Ping Huang1, Jake J Thiessen, Michael Spino, Douglas M Templeton.   

Abstract

Iron chelators are effective at removing iron from the body in iron overload, but little is known about the handling of iron chelates by the kidney. We studied the transport of deferoxamine, deferasirox, and three hydroxypyridones, and their iron chelates, in polarized renal epithelial MDCK cells growing on Transwell inserts. Directional iron efflux was also studied in (59)Fe-loaded cells. The chelators were transported at comparable rates in the apical and basolateral directions and moved faster than their corresponding chelates, except for deferoxamine, which did not move from the basolateral to the apical side. In contrast, the chelates were transported faster in the apical-to-basolateral direction. More permeable chelators were more efficient at removing iron from iron-loaded cells compared with deferoxamine. Iron is preferentially removed from the basolateral side, and kinetic modeling suggests facilitated diffusion of chelates in some cases. Basolateral iron efflux is temperature-dependent and partially sensitive to ATP depletion. Polarized transport of chelates suggests the kidney may be involved in reabsorption of iron bound to chelators, with a temperature-sensitive facilitated removal of some iron complexes from the basolateral side. Further studies are warranted to determine if these processes may contribute to the observed nephrotoxicity of some iron chelators.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213118     DOI: 10.1007/s12185-010-0510-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  60 in total

Review 1.  The roles of cubilin and megalin, two multiligand receptors, in proximal tubule function: possible implication in the progression of renal disease.

Authors:  P J Verroust; R Kozyraki
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-01       Impact factor: 2.894

2.  The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney.

Authors:  H Kulaksiz; F Theilig; S Bachmann; S G Gehrke; D Rost; A Janetzko; Y Cetin; W Stremmel
Journal:  J Endocrinol       Date:  2005-02       Impact factor: 4.286

3.  Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.

Authors:  I Gosriwatana; O Loreal; S Lu; P Brissot; J Porter; R C Hider
Journal:  Anal Biochem       Date:  1999-09-10       Impact factor: 3.365

4.  In vivo characterization of renal iron transport in the anaesthetized rat.

Authors:  M Wareing; C J Ferguson; R Green; D Riccardi; C P Smith
Journal:  J Physiol       Date:  2000-04-15       Impact factor: 5.182

5.  Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.

Authors:  S Singh; R O Epemolu; P S Dobbin; G S Tilbrook; B L Ellis; L A Damani; R C Hider
Journal:  Drug Metab Dispos       Date:  1992 Mar-Apr       Impact factor: 3.922

Review 6.  Deferasirox : a review of its use in the management of transfusional chronic iron overload.

Authors:  Lily P H Yang; Susan J Keam; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Authors:  Alan R Cohen; Renzo Galanello; Antonio Piga; Vincenzo De Sanctis; Fernando Tricta
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

8.  Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat.

Authors:  Carole J Ferguson; Mark Wareing; Mathieu Delannoy; Robert Fenton; Stuart J McLarnon; Nicholas Ashton; Alan G Cox; Raymond F T McMahon; Laura M Garrick; Roger Green; Craig P Smith; Daniela Riccardi
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

9.  Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Authors:  Breno P Esposito; William Breuer; Pornpan Sirankapracha; Pensri Pootrakul; Chaim Hershko; Z Ioav Cabantchik
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

Review 10.  Clinical application of deferasirox: practical patient management.

Authors:  Elliott Vichinsky
Journal:  Am J Hematol       Date:  2008-05       Impact factor: 10.047

View more
  2 in total

Review 1.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

Review 2.  Iron metabolism in the pathogenesis of iron-induced kidney injury.

Authors:  A M F Martines; R Masereeuw; H Tjalsma; J G Hoenderop; J F M Wetzels; D W Swinkels
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.